1. Rapid response to F16-IL2 and LDAC in disseminated extramedullary AML
Rapid response to F16-IL2 and LDAC in disseminated extramedullary AML. A, the figure shows axial 18-FDG-PET/CT scans obtained at baseline before treatment initiation and 14 days after the first infusion (patient 1).
Rapid response to F16-IL2 and LDAC in disseminated extramedullary AML. A, the figure shows axial 18-FDG-PET/CT scans obtained at baseline before treatment initiation and 14 days after the first infusion (patient 1). Pretherapeutic images show disseminated hypermetabolic myelosarcomas (chloromas; SUVmax 14.1) in the left deep cervical area, in the mediastinum, in the hilum of the liver, in the mesentery, in the hilum of the right kidney, in the manubrium of the sternum, in the transverse process of the 9th thoracic vertebra, and subcutaneously in the left gluteal area. The two clinically most critical lesions (left cervical and hilum of the liver) were irradiated between day 4 and day 24 with a cumulative dose of 23.4 Gy in addition to systemic therapy. A complete metabolic response of irradiated and all nonirradiated AML manifestations occurred within 14 days of treatment initiation, which was paralleled by a good partial morphologic remission. B, signs of skin GVHD, which occurred during therapy with F16-IL2 in this patient.
Christoph Schliemann et al. Cancer Immunol Res 2015;3:
©2015 by American Association for Cancer Research